GILD - Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.
COM503 is a potential first-in-class, high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.
Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the ...